Tambe, as the first CEO of the integrated Biocon, will lead the combined platform spanning biosimilars and generics, strengthening the company’s ability to operate at scale and compete effectively in global markets, Biocon said in a statement.
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited.
This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly owned subsidiary of Biocon Limited, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the statement said.
Siddharth Mittal has resigned as CEO and MD of Biocon effective 31 March and will transit into another leadership role within the Biocon Group.
Mukesh Kamath has resigned as Interim Chief Financial Officer of Biocon, effective 31 March, to take up another role within the Biocon Group.
“With the integration of our generics and biosimilars businesses, we are creating a uniquely positioned, globally scaled biopharma enterprise. Shreehas has been at the forefront of this transformation, leading several strategic milestones, including the acquisition and integration of the Viatris biosimilars business and the expansion of our global footprint. Under his leadership, Biocon Biologics has emerged as one of the world’s top five biosimilar companies, with a valuation of USD 5.5 billion. As the first CEO to lead the combined business, Shreehas brings deep scientific expertise, strategic rigor, and a steadfast commitment to advancing affordable healthcare. I am confident he will drive disciplined execution and translate our scale into sustained global leadership,” Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Ltd, said in a statement.
“Biocon is among the few organizations that have transformed access to life-saving treatments by effectively leveraging science and technology. Our success has been driven by exceptional talent, united by a strong sense of purpose and an unwavering commitment to serving patient needs. As we expand our portfolio and global presence, my focus will be on strengthening our foundation, consolidating our business, and accelerating sustainable growth,” Tambe said in a statement.
Tambe joined Biocon nearly three decades ago as a management trainee and, through successive leadership roles, has played a pivotal role in scaling multiple businesses globally.
